Previous 10 | Next 10 |
Kadmon Holdings (NASDAQ:KDMN) +74% Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B Gain Therapeutics (NASDAQ:GANX) +27% on positive GT-02287and GT-02329 data in Parkinson’s disease Alset EHome International (NASDAQ:AEI) +15% inv...
InflaRx received feedback from FDA within its Type A meeting which is supportive of a new primary endpoint measuring reductions in all three inflammatory HS lesions – including reductions of draining tunnels (previously referred to as draining fistulas) InflaRx will focus its...
RenovoRx RNXT +46% after receiving new 510(k) clearance for RenovoCath Delivery System Mechel PAO (NYSE:MTL) +36%. Pliant Therapeutics PLRX +26% on positive PLN-74809 results in Phase 2a IPF study Adaptimmune Therapeutics ADAP +19% and Genentech collaborate to de...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! It’s been a long holiday weekend but we’re jumping right back into the swing of things with a look at the pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com We...
Most are asking is an investment in InflaRx worth it? Presumably, this question is in response to the FDA regulatory hurdle currently playing out with the NDA for avacopan by ChemoCentryx. On ChemoCentryx, you need to read my latest article. Regardless of what is happening at ...
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with dose escalation Treatment of the third cohort with the 2400 mg dose is ongo...
JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the BTIG Virtual Biotechnology Conference on August 10. A BTIG analyst will...
Severe COVID-19 trial enrollment reaches 299 patients; an independent data monitoring committee has recommended to continue the trial as planned after analyzing data from the first 180 evaluable patients Type A meeting request submitted to further discuss primary endpoint for the ...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the Raymond James Human Health Innovation Conference being held Ju...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...